Metropolitan Life Insurance Company (MetLife)’s Abiomed Inc ABMD Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,653	Closed	-$652K	–	2383
2022 Q3	$652K	Sell	2,653 -39	-1%	-$10.5K	0.03%	438
2022 Q2	$666K	Sell	2,692 -64	-2%	-$17.3K	0.03%	454
2022 Q1	$913K	Sell	2,756 -4,433	-62%	-$1.36M	0.03%	435
2021 Q4	$2.58M	Sell	7,189 -119	-2%	-$40.2K	0.04%	417
2021 Q3	$2.38M	Sell	7,308 -234	-3%	-$79.3K	0.03%	427
2021 Q2	$2.35M	Sell	7,542 -235	-3%	-$72.1K	0.03%	450
2021 Q1	$2.48M	Sell	7,777 -448	-5%	-$143K	0.04%	420
2020 Q4	$2.67M	Sell	8,225 -371	-4%	-$103K	0.04%	370
2020 Q3	$2.38M	Sell	8,596 -337	-4%	-$97.1K	0.04%	369
2020 Q2	$2.16M	Buy	8,933 +160	+2%	+$32.1K	0.04%	376
2020 Q1	$1.27M	Sell	8,773 -124	-1%	-$20.6K	0.03%	572
2019 Q4	$1.52M	Sell	8,897 -19	-0.2%	-$3.52K	0.02%	687
2019 Q3	$1.59M	Buy	8,916 +174	+2%	+$37.6K	0.03%	614
2019 Q2	$2.28M	Buy	8,742 +462	+6%	+$123K	0.04%	460
2019 Q1	$2.36M	Sell	8,280 -319	-4%	-$106K	0.04%	403
2018 Q4	$2.8M	Sell	8,599 -20	-0.2%	-$6.95K	0.06%	284
2018 Q3	$3.88M	Buy	8,619 +156	+2%	+$61.5K	0.07%	244
2018 Q2	$3.46M	Sell	8,463 -5,525	-39%	-$2M	0.06%	274
2018 Q1	$4.07M	Buy	13,988 +104	+0.7%	+$26.4K	0.06%	253
2017 Q4	$2.6M	Sell	13,884 -27,370	-66%	-$5.11M	0.03%	390
2017 Q3	$6.96M	Buy	41,254 +1,110	+3%	+$168K	0.04%	383
2017 Q2	$5.75M	Buy	40,144 +841	+2%	+$113K	0.04%	488
2017 Q1	$4.92M	Buy	39,303 +36	+0.1%	+$4.17K	0.03%	601
2016 Q4	$4.42M	Buy	39,267 +52	+0.1%	+$6.02K	0.03%	639
2016 Q3	$5.04M	Buy	39,215 +460	+1%	+$55.1K	0.04%	528
2016 Q2	$4.24M	Sell	38,755 -24,805	-39%	-$2.47M	0.03%	608
2016 Q1	$6.03M	Buy	63,560 +34,230	+117%	+$2.89M	0.05%	416
2015 Q4	$2.65M	Hold	29,330	–	–	0.02%	787
2015 Q3	$2.72M	Sell	29,330 -215	-0.7%	-$18.9K	0.02%	781
2015 Q2	$1.94M	Sell	29,545 -1,689	-5%	-$112K	0.01%	977
2015 Q1	$2.24M	Hold	31,234	–	–	0.02%	866
2014 Q4	$1.19M	Hold	31,234	–	–	0.01%	1220
2014 Q3	$776K	Hold	31,234	–	–	0.01%	1438
2014 Q2	$785K	Hold	31,234	–	–	0.01%	1522
2014 Q1	$813K	Hold	31,234	–	–	0.01%	1489
2013 Q4	$835K	Hold	31,234	–	–	0.01%	1457
2013 Q3	$596K	Hold	31,234	–	–	﹤0.01%	1638
2013 Q2	$673K	Buy	+31,234	New	+$628K	0.01%	1495

Other funds holding ABMD

TRSOTSOK

Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $14.7B AUM 42.39% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Avion Wealth The Woodlands, Texas $537M AUM 18.24% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ABMD Position: Q4 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 2,653 shares — an estimated $652K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ABMD in Q2 2013 and held it in 38 quarters. The position peaked at $6.96M in Q3 2017. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

Metropolitan Life Insurance Company (MetLife) reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 2,653 Abiomed Inc shares in Q4 2022, an estimated $652K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Abiomed Inc in Q2 2013 and held it in 38 quarters.
Metropolitan Life Insurance Company (MetLife)'s Abiomed Inc position peaked at $6.96M in Q3 2017.
8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2022, filed 15 Feb 2023.